Here are relevant reports on : osteoarthritis-therapeutics-market
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Orthobiologics Market by Product (Viscosupplementation, Synthetic Orthobiologics, DBM, BMP, PRP, BMAC, Allograft), Application (Fracture Recovery, Osteoarthritis, Spinal Fusion, Soft Tissue), End User (Hospitals, ASCs, Academia) - Global Forecast to 2022
The global orthobiologics market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period. Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the orthobiologics market. The major players in the market are DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, Bioventus, NuVasive, SeaSpine, Arthrex, and Xtant Medical.
- Published: September 2017
- Price: $ 4950
- TOC Available:
-
Viscosupplementation Market by Product (Single, Three, Five Injection), Application (knee, hip osteoarthritis), Source (animal, non-animal), End-user (Hospitals, Orthopedic Clinics/ASCs), Region (northamerica, Asia Pacific, Europe) - Forecast to 2027
The global Viscosupplementation market size is projected to reach USD XX million by 2027 from USD XX million in 2022, at a CAGR of XX% during the forecast period. The market is driven by factors such as the increasing global prevalence of osteoarthritis, the increasing geriatric population, and the rise in sports injuries. On the other hand, the high cost of products is expected to limit market growth to a certain extent in the coming years.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
mRNA Therapeutics Market by Product (Vaccines, Drugs), Application (Oncology, Rare Diseases, Infectious Diseases, Other Applications), End User (Hospitals & Clinics, Research Settings) - Global Forecast to 2027
The global mRNA therapeutics market is projected to reach USD ~35 billion by 2027 from USD 32 billion in 2022, at a CAGR of ~2% between 2022 and 2027.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Medical Automation Market by Application (Diagnostics & Monitoring, Therapeutics, Lab & Pharmacy Automation, Medical Logistics & Training), End-User (Hospital, Diagnostic Center, Research Institute, Home/Ambulatory Care) - Global Forecast to 2020
The global medical automation market over the forecast period of 2015 to 2020. The market is expected to reach USD 55.03 Billion by 2020, at CAGR of 9.5% from 2015 to 2020. Continuous technological advancements in automation solutions, increasing government financial support for medical automation, rising labour costs, and growing need for reproducibility and accuracy are key factors fuelling the growth of the medical automation market. Increasing demand for automation in laboratories and pharmacies and high potential for early detection and treatment of diseases due to automation are some other prime factors offering growth opportunities for players in the medical automation market. However, high cost of automation is one of the key restraints for this market.
- Published: February 2016
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029
The global microfluidics market, valued at US$21.36 billion in 2023, stood at US$22.43 billion in 2024 and is projected to advance at a resilient CAGR of 7.8% from 2024 to 2029, culminating in a forecasted valuation of US$32.67 billion by the end of the period. The rising requirement of point-of-care diagnostics is an important factor, that helps to detect cancer, infectious diseases, and chronic illnesses, for which microfluidic devices are preferred due to their accuracy.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) & Region - Global Forecast to 2028
The global antibody therapeutics market, valued at US$217.6 billion in 2022, stood at US$247.3 billion in 2023 and is projected to advance at a resilient CAGR of 14.1% from 2023 to 2028, culminating in a forecasted valuation of US$479.0 billion by the end of the period. Growth in the antibody therapeutics market is mainly driven by factors such as growing advancements in antibody engineering for development of novel therapeutics, growing R&D activities among others
- Published: December 2023
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
